ABC | Volume 114, Nº6, June 2020

Viewpoint Wu et al. Preventing Torsades de Pointes during Hydroxychloroquine/Azithromycin Treatment Arq Bras Cardiol. 2020; 114(6):1061-1066 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 02;382(8):727-33. 2. worldometers. https://www.worldometers.info/coronavirus/ [Cited in 2020, April 03] Available from: https://www.worldometers.info/ coronavirus/. 3. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 03;30(3):269-71. 4. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005 Aug;2:69. 5. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-9. 6. U.S. Food and Drug Administration. (FDA) Coronavirus Disease 2019 (COVID - 19) [Cited in 2020 March 28]. Available from: https://www.fda. gov/news-events/press-announcements/coronavirus-covid-19-update- daily-roundup-march-30-2020. 7. Agência Nacional de Vigilância Sanitária. Anvisa. Covid-19: liberada pesquisa com hidroxicloroquina. [Citado em 27 março 2020] Disponível em :http://portal.anvisa.gov.br/ 8. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar:105949. 9. Bacharier LB, Guilbert TW, Mauger DT, Boehmer S, Beigelman A, Fitzpatrick AM, et al. Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Clinical Trial. JAMA. 2015 Nov;314(19):2034-44. 10. Guo D, Cai Y, Chai D, Liang B, Bai N, Wang R. The cardiotoxicity of macrolides: a systematic review. Pharmazie. 2010 Sep;65(9):631-40. 11. Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila). 2006;44(2):173-5. 12. TisdaleJE,JaynesHA,KingeryJR,MouradNA,TrujilloTN,OverholserBR,etal. Development and validation of a risk score to predict QT interval prolongation inhospitalizedpatients.CircCardi.ovascQualOutcomes.2013Jul;6(4):479-87. 13. GiudicessiJR,NoseworthyPA,FriedmanPA,AckermanMJ.UrgentGuidancefor NavigatingandCircumventingtheQTcProlongingandTorsadogenicpotential ofpossiblepharmacotherapiesfor(COVID-19). MayoClinProc.xxx2020:1-9. [In Press] 14. Malviya A. Ventricular Arrhythmia Risk Due to Hydroxychloroquine- Azithromycin Treatment For COVID-19. Indian Heart J. 2020 Apr 27 [Epub ahead of print] 15. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003 May;348(19):1866-74. 16. Johnson JN, Ackerman MJ. QTc: how long is too long? Br J Sports Med. 2009 Sep;43(9):657-62. 17. PostemaPG,WildeAA.ThemeasurementoftheQTinterval.CurrCardiolRev. 2014 Aug;10(3):287-94. 18. El-Sherif N, Turitto G, Boutjdir M. Acquired Long QT Syndrome and Electrophysiology of Torsade de Pointes. Arrhythm Electrophysiol Rev. 2019;8(2):122-30. 19. CredibleMeds.QuicksearchfordrugsontheQTdrugs lists- [Cited in2020Apr 20]. [Available from: crediblemeds.org . 20. Panchal AR, Berg KM, Kudenchuk PJ, Del Rios M, Hirsch KG, Link MS, et al. 2018AmericanHeartAssociationFocusedUpdateonAdvancedCardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2018 12;138(23):e740-e9. 21. SorajjaD,MungerTM,ShenWin-KuangS.Optimalantiarrhythmicdrugtherapy for electrical storm. J Biomed Res. 2015;29(1):20-34. References This is an open-access article distributed under the terms of the Creative Commons Attribution License Table 3 – Pharmacological management of ventricular arrhythmia and/or TdP Lidocaine Loading dose: 1.0 to 1.5 mg/kg IV with repeated doses in bolus, 0.5 – 0.75 mg/kg in a bolus up to 3 mg/kg. Maintenance dose: 20 mcg/kg/min IV. Magnesium sulfate 2 to 4 g IV Isoprotenerol Loading dose: 1 to 2 mcg IV. Maintenance dose: 0.15 mcg/min and titer up to 0.3 mcg/min according to clinical response or necessity. Potential Conflict of Interest The authors report no conflict of interest concerning the materials and methods used in this study or the findings specified in this paper. Sources of Funding There was no external funding source for this study. Study Association This study is not associated with any thesis or dissertation. Ethics approval and consent to participate This article does not contain any studies with human participants or animals performed by any of the authors. revision of the manuscript for intellectual content: Wu TC, Sacilotto L, Darrieux FCC, Pisani CF, Melo SL, Hachul DT, Scanavacca M. 1066